Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
The potential of STAR-LLD to improve lenalidomide’s therapeutic index suggests an opportunity for use in combination with CAR-T cell therapies.As described in the patent application, STAR-LLD's...
-
The potential of STAR-LLD to improve lenalidomide’s therapeutic index suggests an opportunity for use in combination with multi-specific (i.e. bi- and tri-specific) antibodies.Recent Phase 1b trial...
-
Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three doses of STAR-LLD administered by continuous...
-
PARAMUS, N.J., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with...
-
PARAMUS, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous...
-
PARAMUS, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous...
-
PARAMUS, N.J., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous...
-
New U.S. patent provides IP coverage for the formulation to 2042Further expands Starton’s intellectual property portfolio surrounding its lead product candidate, STAR-LLD, Method of Use Patent...
-
PARAMUS, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous...
-
Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigatorSecond site, Regional Medical Oncology Center, also activatedRecent Phase 1b...